Source: Kidney international. Unidade: FM
Subjects: NEFROPATIAS, DIRETRIZES PARA O PLANEJAMENTO EM SAÚDE, RIM
ABNT
TORRES, Vicente E et al. KDIGO 2025 clinical practice guideline for the evaluation, management, and treatment of autosomal dominant polycystic kidney disease (ADPKD): executive summary. Kidney international, v. 107, n. 2, p. 234-254, 2025Tradução . . Disponível em: https://observatorio.fm.usp.br/handle/OPI/82739. Acesso em: 09 out. 2025.APA
Torres, V. E., Ahn, C., Barten, T. R. M., Brosnahan, G., Cadnapaphornchai, M. A., Chapman, A. B., et al. (2025). KDIGO 2025 clinical practice guideline for the evaluation, management, and treatment of autosomal dominant polycystic kidney disease (ADPKD): executive summary. Kidney international, 107( 2), 234-254. doi:10.1016/j.kint.2024.07.010NLM
Torres VE, Ahn C, Barten TRM, Brosnahan G, Cadnapaphornchai MA, Chapman AB, Gall EC-L, Drenth JPH, Gansevoort RT, Onuchic LF. KDIGO 2025 clinical practice guideline for the evaluation, management, and treatment of autosomal dominant polycystic kidney disease (ADPKD): executive summary [Internet]. Kidney international. 2025 ; 107( 2): 234-254.[citado 2025 out. 09 ] Available from: https://observatorio.fm.usp.br/handle/OPI/82739Vancouver
Torres VE, Ahn C, Barten TRM, Brosnahan G, Cadnapaphornchai MA, Chapman AB, Gall EC-L, Drenth JPH, Gansevoort RT, Onuchic LF. KDIGO 2025 clinical practice guideline for the evaluation, management, and treatment of autosomal dominant polycystic kidney disease (ADPKD): executive summary [Internet]. Kidney international. 2025 ; 107( 2): 234-254.[citado 2025 out. 09 ] Available from: https://observatorio.fm.usp.br/handle/OPI/82739